Leukemia patients in remission were treated with either 6-mercaptopurine or a placebo in a clinical trial. Fit survival models for the two groups, compare their estimated survival characteristics, and test whether the treatment is associated with longer remission.
Introduce the remission times for the 6-mercaptopurine group together with censoring indicators, and the remission times for the placebo group:
The 6-mercaptopurine group has a larger estimated median survival and higher estimated survival probabilities over the follow-up period. The log-rank test supports a difference between the two survival distributions.